カテゴリ： GlobalData, ドイツ, 企業調査

Fresenius SE & Co KGaA (FRE)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Fresenius SE & Co KGaA (FRE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8014355
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月22日
◆ページ数：140
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Fresenius SE & Co KGaA (Fresenius) is a global health care group, which offers products and services for dialysis treatment. It provides various dialysis services through its own clinics and sells its products to other dialysis service providers. Its major products and services includes machines for hemodialysis, acute dialysis and peritoneal dialysis; solutions for infusion therapy; dialysis care services; Spectra laboratories; liver support therapy services; and provision projects and services for hospitals and other health care facilities. It also operates and manages acute care and postacute care hospitals in Germany through Helios Kliniken Group. Its major manufacturing plants are in the US, Germany, China, Sweden and Japan. Fresenius conducts operations in Asia-Pacific, Europe, Africa and the Americas. The company is headquartered in Bad Homburg, Hessen, Germany.

Fresenius SE & Co KGaA (FRE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Fresenius SE & Co KGaA, Medical Devices Deals, 2011 to YTD 2017 13
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Fresenius Acquires Biosimilars Business from Merck for USD703 Million 18
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 20
Fresenius Medical Care Acquires Therapeutic Apheresis Assets from HemaCare 21
Sound Inpatient Physicians Acquires Certain Assets from Inpatient Specialists 22
Fresenius Completes Acquisition Of 38 Hospitals And 11 Outpatient Facilities From Rhon-Klinikum 23
Sound Inpatient Physicians Acquires Certain Assets Of Inpatient Care Unified 25
Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For US$37 Million 26
APP Pharma Acquires Three Critical Care Products From Nexus Pharma 27
Fresenius Medical Care Acquires Eight Dialysis Clinics in Ecuador 28
Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 29
Fresenius To Acquire German Hospitals 31
Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 32
Venture Financing 33
Fresenius Medical Care Elgin Raises US$3 Million In Venture Financing 33
Fresenius Medical Care Palatine Raises US$3 Million In Venture Financing 34
Fresenius Medical Care Raises US$5.5 Million In Venture Financing 35
Fresenius Vascular Care Raises US$0.3 Million In Venture Financing 36
Noro-Moseley Partners Acquires Minority Stake In Diabetes Care Group From Renal Care Group 37
Fresenius Medical Care Batavia Raises US$1.8 Million In Venture Financing 38
Fresenius Medical Care West Raises US$2.3 Million In Venture Financing 39
Fresenius Medical Care Enid Raises US$2.4 Million In Venture Financing 40
Fresenius Medical Care Pomona To Raise US$2.56 Million In Venture Financing 41
Partnerships 42
Spectral Medical Enters into Agreement with Fresenius Medical Care Deutschland 42
CytoSorbents Enters into Distribution Agreement with Fresenius Medical Care for CytoSorb Therapy 43
Partners HealthCare to Form Joint Venture with MedSpring Urgent Care 44
Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 45
Apollo Medical Enters Into Agreement With Fresenius Medical Care For End Stage Renal Disease 46
Heritage California Enters Into Agreement With Fresenius Medical For End Stage Renal Disease 47
Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 48
Huons Enters Into Co-Promotion Agreement With Fresenius Kabi For Fresofol 49
Handok Pharma Enters Into Co-Marketing Agreement With Fresenius Kabi 50
Licensing Agreements 51
Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 51
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 52
Toray Industries Enters Into Licensing Agreement With Fresenius Medical Care For TRK-820 53
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 54
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI 55
Equity Offering 56
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 56
Debt Offering 57
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 57
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 58
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 59
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 60
Fresenius Raises USD300 Million in Private Placement of Notes 61
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 62
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 63
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 64
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 65
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 66
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 68
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 69
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 70
Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 71
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 72
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 73
Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 74
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 75
Asset Transactions 76
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 76
Davita Acquires Nine Dialysis Centers From Fresenius Medical Care 77
DSI Renal Acquires 54 Dialysis Clinics From Fresenius Medical Care North America 78
Acquisition 79
Fresenius to Acquire Akorn 79
NewCo Pharma Acquires CFL from Fresenius Kabi 81
Sound Physicians Acquires Cogent Healthcare 82
Fresenius Medical Care to Acquire National Cardiovascular 83
Fresenius Kabi Acquires Novafarma Industria Farmaceutica 84
Berenberg Acquires 5% Stake in Rhoen-Klinikum from Fresenius 85
Fresenius Medical Care Acquires MedSpring Urgent Care 86
Fresenius Medical Care to Acquire Majority Stake in Sound Inpatient Physicians for USD600 Million 87
Fresenius Kabi To Acquire 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare For US$200 Million 88
Neopharm Acquires Biotech Arm Of Fresenius 89
Fresenius Kabi (Singapore) To Delist Its Indian Arm 90
Linde To Acquire Calea France From Fresenius Kabi 91
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 92
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 94
Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 95
Fresenius Medical Care Completes Acquisition Of Liberty Dialysis Holdings For US$1.7 Billion 96
Fresenius Medical Care Acquires Eastview Dialysis 98
Fresenius Medical Care Completes Acquisition Of American Access Care Holdings For US$385 Million 99
Sound Inpatient Acquires Bay Area Inpatient 100
Fresenius SE & Co KGaA – Key Competitors 101
Fresenius SE & Co KGaA – Key Employees 102
Fresenius SE & Co KGaA – Locations And Subsidiaries 103
Head Office 103
Other Locations & Subsidiaries 103
Recent Developments 108
Strategy And Business Planning 108
Oct 19, 2017: Fresenius Vamed opens Institute for Gender Medicine 108
Jun 08, 2017: Fresenius Medical Care sees excellent prospects for further growth and launches a new Global Efficiency Program at its Capital Markets Day 2017 109
Nov 22, 2016: HELIOS lays foundation stone for new hospital building in Wiesbaden 110
Sep 01, 2016: Fresenius Vamed completes first building phase at University Hospital Schleswig-Holstein 111
Apr 08, 2016: Fresenius Vamed lays foundation stone for new university hospital building 112
Financial Announcements 113
Aug 01, 2017: Fresenius confirms its guidance after a strong second quarter with double-digit sales and earnings growth 113
Oct 27, 2016: Fresenius: Continued strong sales and earnings growth; Lower end of Group earnings guidance raised 116
Aug 01, 2016: Fresenius Medical Care posts accelerated earnings growth in the 2nd quarter 120
May 03, 2016: Strong start into the year – Double-digit earnings growth in constant currency – Fresenius confirms Group guidance for 2016 123
Feb 24, 2016: Outstanding 2015 financial results – 25% dividend increase proposed – Positive outlook for 2016 – New mid-term growth targets 125
Corporate Communications 129
Jul 21, 2017: Fresenius appoints Rachel Empey as Chief Financial Officer 129
Jan 13, 2017: Fresenius Medical Care Announces Leadership Change in North America 130
Jun 26, 2016: Fresenius appoints Stephan Sturm as new Chief Executive Officer – Ulf Mark Schneider leaves the company to pursue another opportunity 131
Legal and Regulatory 132
Jan 31, 2017: Fresenius Medical Care reaches agreement on outstanding payments 132
Jan 26, 2017: U.S. District Court Issues Preliminary Injunction Against Premium Assistance Regulation 133
Clinical Trials 134
Mar 02, 2016: Merck Initiates Phase III Study of MSB11022, a Proposed Biosimilar of Adalimumab, in Chronic Plaque Psoriasis 134
Other Significant Developments 135
Aug 22, 2017: Fresenius Helios invests in German hospital network 135
Jul 12, 2017: Fresenius Medical Care successfully amends and extends its credit agreement, ahead of schedule 136
Sep 08, 2016: Fresenius Helios expands hospital in Hildesheim 137
Aug 17, 2016: Fresenius Kabi investing nearly $250 million to expand plant near Chicago 138
Jun 08, 2016: HELIOS invests in new hospital building in Duisburg, Germany 139
Appendix 140
Methodology 140
About GlobalData 140
Contact Us 140
Disclaimer 140

List of Tables
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Fresenius SE & Co KGaA, Deals By Therapy Area, 2011 to YTD 2017 11
Fresenius SE & Co KGaA, Medical Devices Deals, 2011 to YTD 2017 13
Fresenius SE & Co KGaA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Fresenius Acquires Biosimilars Business from Merck for USD703 Million 18
Fresenius Kabi USA Acquires US Pharma Plant and Ready to Administer Drugs from Becton, Dickinson 20
Fresenius Medical Care Acquires Therapeutic Apheresis Assets from HemaCare 21
Sound Inpatient Physicians Acquires Certain Assets from Inpatient Specialists 22
Fresenius Completes Acquisition Of 38 Hospitals And 11 Outpatient Facilities From Rhon-Klinikum 23
Sound Inpatient Physicians Acquires Certain Assets Of Inpatient Care Unified 25
Fresenius Kabi India To Acquire Manufacturing Unit Of Goa Formulations For US$37 Million 26
APP Pharma Acquires Three Critical Care Products From Nexus Pharma 27
Fresenius Medical Care Acquires Eight Dialysis Clinics in Ecuador 28
Fresenius Medical Care Completes Acquisition Of International Dialysis Centers From Euromedic International 29
Fresenius To Acquire German Hospitals 31
Fresenius Medical Care Acquires Crit-Line System Assets From Hema Metrics 32
Fresenius Medical Care Elgin Raises US$3 Million In Venture Financing 33
Fresenius Medical Care Palatine Raises US$3 Million In Venture Financing 34
Fresenius Medical Care Raises US$5.5 Million In Venture Financing 35
Fresenius Vascular Care Raises US$0.3 Million In Venture Financing 36
Noro-Moseley Partners Acquires Minority Stake In Diabetes Care Group From Renal Care Group 37
Fresenius Medical Care Batavia Raises US$1.8 Million In Venture Financing 38
Fresenius Medical Care West Raises US$2.3 Million In Venture Financing 39
Fresenius Medical Care Enid Raises US$2.4 Million In Venture Financing 40
Fresenius Medical Care Pomona To Raise US$2.56 Million In Venture Financing 41
Spectral Medical Enters into Agreement with Fresenius Medical Care Deutschland 42
CytoSorbents Enters into Distribution Agreement with Fresenius Medical Care for CytoSorb Therapy 43
Partners HealthCare to Form Joint Venture with MedSpring Urgent Care 44
Otsuka Pharma Factory Enters Into Distribution Agreement With Fresenius Kabi Japan For HES Products 45
Apollo Medical Enters Into Agreement With Fresenius Medical Care For End Stage Renal Disease 46
Heritage California Enters Into Agreement With Fresenius Medical For End Stage Renal Disease 47
Provepharm Enters Into Distribution Agreement With Fresenius Kabi Pharma 48
Huons Enters Into Co-Promotion Agreement With Fresenius Kabi For Fresofol 49
Handok Pharma Enters Into Co-Marketing Agreement With Fresenius Kabi 50
Caplin Point Laboratories Enters into Licensing and Distribution Agreement with Fresenius Kabi USA 51
InnoPharma Enters Into Licensing Agreement With Fresenius Kabi For Acetylcysteine Solution 52
Toray Industries Enters Into Licensing Agreement With Fresenius Medical Care For TRK-820 53
Medicines Company Enters Into Licensing Agreement With APP For Acute Care Generic Products 54
APP Pharma Enters Into Licensing Agreement With Teva Pharma For Gemcitabine HCI 55
Fresenius Plans Private Placement Of Shares For US$1.3 Billion 56
Fresenius Raises USD530.4 Million in Private Placement of 3% Notes Due 2032 57
Fresenius Raises USD742.5 Million in Private Placement of 0.875% Notes Due 2022 58
Fresenius Raises USD742.5 Million in Private Placement of 1.5% Notes Due 2024 59
Fresenius Raises USD742.5 Million in Private Placement of 2.125% Notes Due 2027 60
Fresenius Raises USD300 Million in Private Placement of Notes 61
Fresenius Medical Care Raises USD518 Million in Private Placement of Convertible Bonds 62
Fresenius Increases Size Of Private Placement Of Notes Due 2024 For US$611.4 Million 63
Fresenius Completes Private Placement Of Notes Due 2019 For US$407.6 Million 64
Fresenius Completes Private Placement Of Notes Due 2021 For US$611.4 Million 65
Fresenius Medical Care Prices Private Placement Of Notes Due 2020 For US$673 Million 66
Fresenius Medical Care Completes Private Placement Of 5.625% Senior Unsecured Notes Due 2019 For US$800 Million 68
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2019 For US$316.4 Million 69
Fresenius Medical Care Completes Private Placement Of 5.875% Senior Unsecured Notes Due 2022 For US$700 Million 70
Fresenius Medical Care Completes Private Placement Of Floating-Rate Senior Notes Due 2016 For US$133.7 Million 71
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$550 Million 72
Fresenius Medical Care Completes Private Placement Of Senior Unsecured Notes Due 2018 For US$400 Million 73
Fresenius Medical Care Completes Private Placement Of 5.75% Senior Unsecured Notes Due 2021 For US$650 Million 74
Fresenius Medical Care Completes Private Placement Of 5.25% Senior Unsecured Notes Due 2021 For US$403 Million 75
Xellia Acquires Lyophilized Manufacturing Facility from Fresenius Kabi 76
Davita Acquires Nine Dialysis Centers From Fresenius Medical Care 77
DSI Renal Acquires 54 Dialysis Clinics From Fresenius Medical Care North America 78
Fresenius to Acquire Akorn 79
NewCo Pharma Acquires CFL from Fresenius Kabi 81
Sound Physicians Acquires Cogent Healthcare 82
Fresenius Medical Care to Acquire National Cardiovascular 83
Fresenius Kabi Acquires Novafarma Industria Farmaceutica 84
Berenberg Acquires 5% Stake in Rhoen-Klinikum from Fresenius 85
Fresenius Medical Care Acquires MedSpring Urgent Care 86
Fresenius Medical Care to Acquire Majority Stake in Sound Inpatient Physicians for USD600 Million 87
Fresenius Kabi To Acquire 51% Stake in Ethica Industri Farmasi From Soho Global Halthcare For US$200 Million 88
Neopharm Acquires Biotech Arm Of Fresenius 89
Fresenius Kabi (Singapore) To Delist Its Indian Arm 90
Linde To Acquire Calea France From Fresenius Kabi 91
Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For US$1.1 Billion 92
Fresenius Acquires 70% Stake In Huangshi Lishizhen Medicine Group Wuhan Xisu Pharma From Huangshi Lishizhen Medicine Group Wuhan Lishizhen Medicine 94
Fresenius Kabi Plans To Sell 15% Stake In Fresenius Kabi Oncology 95
Fresenius Medical Care Completes Acquisition Of Liberty Dialysis Holdings For US$1.7 Billion 96
Fresenius Medical Care Acquires Eastview Dialysis 98
Fresenius Medical Care Completes Acquisition Of American Access Care Holdings For US$385 Million 99
Sound Inpatient Acquires Bay Area Inpatient 100
Fresenius SE & Co KGaA, Key Competitors 101
Fresenius SE & Co KGaA, Key Employees 102
Fresenius SE & Co KGaA, Other Locations 103
Fresenius SE & Co KGaA, Subsidiaries 103

★海外企業調査レポート[Fresenius SE & Co KGaA (FRE)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Shanghai ChemPartner Co Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Shanghai ChemPartner Co Ltd (ChemPartner) is a life science contract research organization. The organization’s services include manufacturing of small molecules and biologics, drug discovery and development, biomarkers, preclinical and clinical sample bioanalysis, and analytical services, am …
  • Emcure Pharmaceuticals Ltd：企業の戦略的SWOT分析
    Emcure Pharmaceuticals Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • 7-Eleven Inc：企業のM&A・事業提携・投資動向
    7-Eleven Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's 7-Eleven Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • HIL Limited (HIL)：企業の財務・戦略的SWOT分析
    HIL Limited (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Savara Inc (SVRA)：医療機器：M&Aディール及び事業提携情報
    Summary Savara Inc (Savara) formerly Mast Therapeutics Inc is a clinical stage biopharmaceutical company, which develops therapies for the treatment of rare respiratory diseases, including cystic fibrosis (CF), and pulmonary alveolar proteinosis (PAP). The company’s lead product candidates include M …
  • Inner Mongolia Yili Industrial Group Co Ltd：企業の戦略・SWOT・財務分析
    Inner Mongolia Yili Industrial Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Inner Mongolia Yili Industrial Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation …
  • Meiji Holdings Co, Ltd.：戦略・SWOT・企業財務分析
    Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Meiji Holdings Co, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Digirad Corp (DRAD)：医療機器：M&Aディール及び事業提携情報
    Summary Digirad Corp (Digirad) is a medical device company that provides mobile and on-site imaging solutions. The company provides camera products such as ergo, cardius x-ACT, cardius 2 XPO, corcam, quantumcam, cardius 3 XPO, and others. It provides diagnostic services such as nuclear cardiology, u …
  • PT. Millennium Pharmacon International TBK (SDPC)：企業の財務・戦略的SWOT分析
    PT. Millennium Pharmacon International TBK (SDPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • DSM Dyneema BV：企業の戦略的SWOT分析
    DSM Dyneema BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Hafslund AS：企業の戦略・SWOT・財務情報
    Hafslund AS - Strategy, SWOT and Corporate Finance Report Summary Hafslund AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Sonoma Pharmaceuticals Inc (SNOA)：医療機器：M&Aディール及び事業提携情報
    Summary Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences, is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue care. The company offers products for ad …
  • Velesto Energy Bhd (UMWOG)：石油・ガス：M&Aディール及び事業提携情報
    Summary Velesto Energy Bhd (Velesto) formerly UMW Oil & Gas Corp Bhd, a subsidiary of UMW Holdings Bhd, is an oil and gas company that offers drilling and oilfield services. The company’s services include offshore drilling, hydraulic workover services, threading, inspection and repair services. Its …
  • Oceaneering International Inc (OII)：石油・ガス：M&Aディール及び事業提携情報
    Summary Oceaneering International Inc (Oceaneering) is an oilfield provider of engineered products and services. The company serves primarily the offshore oil and gas industry, with a focus on deepwater applications. Its oilfield products and services include remotely operated vehicles, specialty su …
  • Coresa Sa
    Coresa Sa - Strategy, SWOT and Corporate Finance Report Summary Coresa Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Asia Paper Manufacturing Co., Ltd.：企業の戦略・SWOT・財務情報
    Asia Paper Manufacturing Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Asia Paper Manufacturing Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Dentsu International Ltd：企業の戦略的SWOT分析
    Dentsu International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • D. Western Therapeutics Institute Inc (4576)：製薬・医療：M&Aディール及び事業提携情報
    Summary D. Western Therapeutics Institute Inc (DWTI) is a pharmaceutical product s developer. The company offers ophthalmic solution, WP-1303, H-1337, K-134 and DW-1002. It discovers and develops drugs for glaucoma. DWTI’s ophthalmic solution treats glaucoma and ocular hypertension treatment and art …
  • Yung Shin Pharma Ind Co Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Yung Shin Pharma Ind Co Ltd (Yung Shin Pharma), a subsidiary of YungShin Global Holding Corporation is a distributor of veterinary drugs, diagnostic kits and active pharmaceutical drugs. The company’s products include carlipin, glix, macgel, diabetin, domper, kascoal, biotase, bisacodyl and …
  • Kulim (Malaysia) Bhd：企業の戦略的SWOT分析
    Kulim (Malaysia) Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆